Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Five Below’s stocks faced a heavy downturn, plummeting 27.81% to finish at $58.83. The steep drop coincided with overarching market fears stemming from President Donald Trump's tariff plan, which ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

Eli Lilly’s stock slipped during a broader market nosedive sparked by Trump’s tariff barrage, but retail traders oddly found ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...

Eli Lilly licenses Sangamo's BBB-penetrating AAV capsid for CNS disease with $18M upfront; deal includes option for 4 more ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as ...

Shares of Eli Lilly & Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by ...

Sangamo Therapeutics Inc. has entered into a license agreement with Eli Lilly and Co., allowing Lilly to use Sangamo’s novel proprietary neurotropic AAV capsid, STAC-BBB, to deliver intravenously ...